- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Conferences
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
- Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Monday, Pliant Therapeutics Inc (PLRX:NSQ) closed at 15.12, 34.88% above the 52 week low of 11.21 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.33 |
---|---|
High | 15.87 |
Low | 15.09 |
Bid | 15.00 |
Offer | 16.55 |
Previous close | 15.27 |
Average volume | 620.20k |
---|---|
Shares outstanding | 60.33m |
Free float | 56.46m |
P/E (TTM) | -- |
Market cap | 921.18m USD |
EPS (TTM) | -2.86 USD |
Data delayed at least 15 minutes, as of May 20 2024 21:00 BST.
More ▼